ASPCR vs GILD
A SPAC III Acquisition Corp. Right (ASPCR) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
A SPAC III Acquisition Corp. Right (ASPCR) common stock listed on US.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
ASPCR does not have a complete income-statement cache yet.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
ASPCR currently screens at market cap $0. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the ASPCR and GILD stock pages for the full models.
Not investment advice.